

MILESTONES	STATUS	MILESTONES	MILESTONES	MILESTONES	MILESTONES	MILESTONES	MILESTONES	MILESTONES	PROJECTED MILESTONES COMPLETED
Initial 6 months		Months 7-14	Months 14-20	Months 20-26 (end of YR2)	YR3	YR4	YR5	YR6	
GPR68-Cre	Done	Construction of 6 additional mouse lines	Construction and characterization of 6-12 additional mouse lines	Continue with 6-12 mouse lines	Construction and characterization of 6-12 additional mouse lines	Construction and characterization of 6-12 additional mouse lines	Construction and characterization of 6-12 additional mouse lines	Construction and characterization of 6-12 additional mouse lines	60-80 mouse lines characterized and deposited to repository
Tas2R108 [Tas2R4 mouse homologue] GPR85	Breeding Breeding								
Additional 6 mouse lines for Y prioritized via consultation with Program Staff Determination of which DREADD constructs should be advanced with advice from NIH WG		Prioritization of 6-12 mouse lines for Year 2 via consultation with Program Staff and consultants	Prioritization of 6-12 mouse lines for Year 3 via consultation with Program Staff and consultants		Prioritization of 6-12 mouse lines for Year 4 via consultation with Program Staff and consultants	Prioritization of 6-12 mouse lines for Year 5 via consultation with Program Staff and consultants	Prioritization of 6-12 mouse lines for Year 6 via consultation with Program Staff and consultants		
Anatomical distribution of oGPCRs validated for 3 mouse lines		Anatomical distribution of oGPCRs for 6 additional mouse lines	Anatomical distribution of oGPCRs for 6 additional mouse lines	Anatomical distribution of oGPCRs for 6 additional mouse lines	Anatomical distribution of oGPCRs for 6-12 additional mouse lines	Anatomical distribution of oGPCRs for 6-12 additional mouse lines	Anatomical distribution of oGPCRs for 6-12 additional mouse lines	Anatomical distribution of oGPCRs for 6-12 additional mouse lines	
GPR68	In progress								
Probes developed for 2 oGPCRs		Probes developed for 2 oGPCRs in consultation with program staff and consultants	Probes developed for 2 oGPCRs in consultation with program staff and consultants	Probes developed for 2 oGPCRs in consultation with program staff and consultants	Probes developed for 5-10 oGPCRs in consultation with program staff and consultants	Probes developed for 5-10 oGPCRs in consultation with program staff and consultants	Probes developed for 5-10 oGPCRs in consultation with program staff and consultants	Probes developed for 5-10 oGPCRs in consultation with program staff and consultants	~40 probes developed and made available, hits for another ~40 oGPCRs characterized
MRGPRX4	In progress								
htr5A	In progress	Review criteria and update official understudied GPCR list; success is approval by IDG SC and NIH							
Additional oGPCRs prioritized for probe development in YR1		Additional oGPCRs prioritized for probe development in YR2							
Meeting with consultants at UNC or UCSF		Meeting with consultants at UNC or UCSF	Meeting with consultants at UNC or UCSF		Meeting with consultants at UNC or UCSF	Meeting with consultants at UNC or UCSF	Meeting with consultants at UNC or UCSF	Meeting with consultants at UNC or UCSF	
Decision made on 10% set-aside for collaborative studies with IDG participants.		Agreement reached for deposition of prepublication data							

MILESTONES	STATUS	MILESTONES	MILESTONES	MILESTONES	MILESTONES	MILESTONES	MILESTONES	MILESTONES	MILESTONES	PROJECTED MILESTONES COMPLETED
Initial 6 months		Months 7-14	Months 14-20	Months 20-26 (end of YR2)	YR3	YR4	YR5	YR6		
MOUSE Lines deposited to JAX or MMRC			MOUSE Lines deposited to JAX or MMRC Assessment of rigor, reproducibility and reliability of experiments from YR1 and emerging YR2 data; successful completion of this milestone as assessed by NIH and WG	MOUSE Lines deposited to JAX or MMRC	MOUSE Lines deposited to JAX or MMRC	MOUSE Lines deposited to JAX or MMRC	MOUSE Lines deposited to JAX or MMRC	MOUSE Lines deposited to JAX or MMRC	MOUSE Lines deposited to JAX or MMRC	
Probes made available via SIGMA		Work with IDG SC to harmonize and minimize the list of depositories for data and reagents	Probes made available via SIGMA	Probes made available via SIGMA	Probes made available via SIGMA	Probes made available via SIGMA	Probes made available via SIGMA	Probes made available via SIGMA	Probes made available via SIGMA	
Initial plans for dissemination of pre-publication data		Assessment of success rate and potential alteration of throughput for probe development	Pre-publication data shared	Pre-publication data shared	Pre-publication data shared	Pre-publication data shared	Pre-publication data shared	Pre-publication data shared	Pre-publication data shared	ALL RELEVANT DATA OPEN-SOURCE VIA PHAROS OR OTHER REPOSITORY
Homology modeling & docking for 4 oGPCRs (HTR5, MRGRPX4, CHRM5, HTR1E)	in progress	Modeling and docking against 4 oGPCRs in consultation with program staff and consultants, and drawing off of physical screens in Roth lab	Modeling and docking against 4 oGPCRs in consultation with program staff and consultants, and drawing off of physical screens in Roth lab	Modeling and docking against 4 oGPCRs in consultation with program staff and consultants, and drawing off of physical screens in Roth lab	Modeling and docking against 5-10 oGPCRs in consultation with program staff and consultants	Modeling and docking against 5-10 oGPCRs in consultation with program staff and consultants	Modeling and docking against 5-10 oGPCRs in consultation with program staff and consultants	Modeling and docking against 5-10 oGPCRs in consultation with program staff and consultants	Modeling and docking against 5-10 oGPCRs in consultation with program staff and consultants	Models developed and docking screens prosecuted for about 8 oGPCRs.
Library development: analysis of Roth lab library for chemotype holes.	in progress	Filling chemotype holes in physical library by purchasing new compounds	Filling chemotype holes in physical library by purchasing new compounds	Filling chemotype holes in physical library by purchasing new compounds, ideally also with additions from Pharma chemogenomics libraries (stretch objective)	Filling chemotype holes in physical library by purchasing new compounds, ideally also with additions from Pharma chemogenomics libraries (stretch objective)	Filling chemotype holes in physical library by purchasing new compounds, ideally also with additions from Pharma chemogenomics libraries (stretch objective)	Filling chemotype holes in physical library by purchasing new compounds, ideally also with additions from Pharma chemogenomics libraries (stretch objective)	Filling chemotype holes in physical library by purchasing new compounds, ideally also with additions from Pharma chemogenomics libraries (stretch objective)	Filling chemotype holes in physical library by purchasing new compounds, ideally also with additions from Pharma chemogenomics libraries (stretch objective)	
Expanding dockable ZINC library to 100 million compounds	in progress	Expanding dockable ZINC library to 200 million compounds	Expanding dockable ZINC library to 250 million compounds	Expanding dockable ZINC library to 300 million compounds						
		End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	End of Year: Project Deliverables, Milestones, Decision Tree, Endpoints, and Timeline, success being approval by the NIH.	